Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China

Current HIV Research

Volumn 9, Issue 2, 2011, Pages 103-111

  Wang, Xia ^a   Yang, Liting ^a   Li, Huiqin ^b   Zuo, La ^c   Liang, Shujia ^d   Liu, Wei ^d   Dong, Yonghui ^c   Yang, Shaomin ^b   Shang, Hong ^e   Li, Jingyun ^f   Kang, Laiyi ^g   Zhong, Ping ^g   Zheng, Wei ^a   Liao, Lingjie ^a   Xing, Hui ^a   Chen, Ray Y ^h   Ruan, Yuhua ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Yunnan Infectious Disease Hospital   (China)

^c Xinjiang Center for Disease Prevention and Control   (China)

^d GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^g SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antiretroviral therapy; China; HIV drug resistance; HIV drug resistance prevention; HIV RNA

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK FACTOR; SENTINEL SURVEILLANCE; VIROLOGY; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

EID: 79953298990     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016211795569122     Document Type: Article

References (36)

1. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341(25): 1865-1873.
2. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15(1): F1-F9.
3. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368(9553): 2125-2135.
4. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151(4): 241-251, W-252.
5. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008; 47(6): 825-833.
6. Li JY, Li HP, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res 2005; 15(11-12): 843-849.
7. Liao L, Xing H, Shang H, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 2010; 53(Suppl 1): S10-S14.
8. Zhang M, Han XX, Cui WG, et al. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis 2008; 61(5): 361-365.
9. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2): 15-23.
10. Cohen J. HIV/AIDS in China. Poised for takeoff? Science 2004; 304(5676): 1430-1432.
11. Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature 2008; 455(7213): 609-611.
12. Zhang F. National free HIV antiretroviral treatment handbook. 2nded. Beijing, China: People's Medical Publishing House 2008.
13. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010; 50(2): 264-271.
14. Ma Y, Zhang F, Zhao Y, et al. Cohort Profile: The Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010; 39(4): 973-979.
15. Zhong P, Pan Q, Ning Z, et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 2007; 23(7): 847-856.
16. Jiang Y, Qiu M, Zhang G, et al. Quality assurance in the HIV/AIDS laboratory network of China. Int J Epidemiol 2010; 39(Suppl 2): 1172-1178.
17. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16(10): 1363-1370.
18. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000; 14(9): 1171-1180.
19. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18(Suppl 3): S21-S25.
20. Smith D, Berrey MM, Robertson M, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182(3): 950-954.
21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337(11): 725-733.
22. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337(11): 734-739.
23. Boileau C, Nguyen VK, Sylla M, et al. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48(4): 476-484.
24. Fielding KL, Charalambous S, Stenson AL, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008; 8: 93.
25. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008; 49(1): 107-110.
26. Rodriguez-Arenas MA, Jarrin I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006; 22(8): 715-723.
27. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15(9): 1115-1123.
28. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131(2): 81-87.
29. Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007; 21(Suppl 8): S143-S148.
30. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37(8): 1112-1118.
31. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137(5 Pt 2): 381-433.
32. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296(7): 782-793.
33. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14(4): 357-366.
34. Costagliola D, Descamps D, Assoumou L, et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46(1): 12-18.
35. Hanson DL, Adje-Toure C, Talla-Nzussouo N, et al. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2009; 25(5): 489-495.
36. Vergne L, Kane CT, Laurent C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003; 17(Suppl 3): S31-S38.